AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22629840
Drug: Standard 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 150 Mbk injection (Control)
Trial: 20558431
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aliskiren and Valsartan
Trial: 20558431
Drug: Active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapy (Aliskiren, Valsartan, Combination)
Trial: 18377854
Drug: Hypnotic analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic analgesia intervention 20 minutes before and throughout the surgical procedure
Trial: 18377854
Drug: Hypnotic analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic analgesia intervention
Trial: 12823307
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine for confirmed dermatophyte onychomycosis for 12 weeks
Trial: 11880064
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (PPS) therapy at doses of 300, 600, or 900 mg/day for 32 weeks
Trial: 10025931
Drug: HCQ 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ 400 mg/day
Trial: 10025931
Drug: HCQ 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ 800 mg/day
Trial: 10025931
Drug: HCQ 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ 1200 mg/day
Trial: 10025931
Drug: Naproxen (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (1,000 mg/day)
Trial: 7546934
Drug: High-dose botulinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose botulinum toxin type A (240 units/session)
Trial: 7546934
Drug: Medium-dose botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose botulinum toxin type A (120 units/session)
Trial: 7546934
Drug: Low-dose botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose botulinum toxin type A (60 units/session)
Trial: 6452842
Drug: Ipratropium nasal
RxNorm normalized name: ipratropium nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium nasal spray (80 micrograms, 4 times daily for 1 week)
Trial: 24072451
Drug: Dronedarone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone (400 mg twice daily)
Trial: 18594127
Drug: Medio/Lateral (M/L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medio/Lateral (M/L) training
Trial: 15220949
Drug: Trans fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans fatty acids (TFA) - 33 g daily intake from partially hydrogenated soy oil containing 20 g of TFA
Trial: 15220949
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFA) - 33 g daily intake from fish oil with approximately 4 g of n-3 PUFA
Trial: 15220949
Drug: Control fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control fat - 33 g daily intake of control fat
Trial: 9924276
Drug: Control +
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control + 50 g sugarbeet fibre/d
Trial: 9924276
Drug: Control +
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control + 50 g commercial inulin/d
Trial: 29747834
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg folic acid + 10 mg enalapril
Trial: 27622219
Drug: Omega-3 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (1000 mg capsules for 6 months)
Trial: 20573635
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg (2 doses: 2 h before surgery and on first postoperative day)
Trial: 10868864
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg) plus Metformin (500 mg)
Trial: 9268758
Drug: Itraconazole 300
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 300 mg/day (Group 1)
Trial: 9268758
Drug: Itraconazole 300
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 300 mg/day followed by cryosurgery (Group 3)
Trial: 3955536
Drug: Beta-carotene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (180 mg/week for 16 weeks)
Trial: 3955536
Drug: Beta-carotene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (180 mg/week for 16 weeks) plus vitamin A (100,000 IU/week for 16 weeks)
Trial: 3046484
Drug: Cephalexin hydrochloride
RxNorm normalized name: Cephalexin Hydrochloride
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin hydrochloride (250 mg four times a day) in study A
Trial: 3046484
Drug: Cephalexin monohydrate
RxNorm normalized name: Cephalexin Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin monohydrate (500 mg two times a day) in study A
Trial: 3046484
Drug: Cephalexin hydrochloride
RxNorm normalized name: Cephalexin Hydrochloride
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin hydrochloride (500 mg two times a day) in study B
Trial: 3046484
Drug: Cephalexin monohydrate
RxNorm normalized name: Cephalexin Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin monohydrate (250 mg four times a day) in study B
Trial: 3046484
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (cephalexin hydrochloride and cephalexin monohydrate)
Trial: 19916311
Drug: Air-ozone baths
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-ozone baths (20 minutes, ozone concentration 8-10 mg/l, temperature 36 degrees C, 10 daily procedures)
Trial: 19916311
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 patients without operational treatment)
Trial: 7580021
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of hMG (75 IU/day) in desensitization protocol
Trial: 7580021
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of hMG (75 IU/day) in flare-up protocol
Trial: 27036360
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (40mcg/day per nostril) intranasal spray for 6 months, starting at postoperative week 3 after wound healing
Trial: 27036360
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline spray
Trial: 25539418
Drug: Nobori drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nobori drug-eluting stent
Trial: 25539418
Drug: TAXUS drug-eluting
RxNorm normalized name: Taxus baccata fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAXUS drug-eluting stent
Trial: 23809343
Drug: Surfactant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant therapy (given prophylactically or in established RDS)
Trial: 10830075
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (15 ml ropivacaine 7.5 mg/ml with fentanyl 100 micrograms)
Trial: 2004920
Drug: Heparin 4
RxNorm normalized name: heparin 40000 units/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 4 U/ml in 0.9% sodium chloride
Trial: 6192514
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin combined with dihydroergotamine
Trial: 30415637
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 fatty acids (1 g per day)
Trial: 26291629
Drug: Telephone and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone and in‐person cognitive‐behavioral therapy
Trial: 24064511
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg IC43 with adjuvant
Trial: 24064511
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg IC43 with adjuvant
Trial: 24064511
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg IC43 with adjuvant
Trial: 24064511
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg IC43 without adjuvant
Trial: 22511052
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy containing doxycycline (Group A): esomeprazole 20 mg, bismuth potassium citrate 220 mg, amoxicillin 1 g, doxycycline 100 mg, all bid for ten days.
Trial: 22511052
Drug: Routine quadruple
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine quadruple therapy (Group B): esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, metronidazole 400 mg bid, tetracycline 750 mg q.6h, for ten days.
Trial: 12529345
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy immediately following surgery
Trial: 12529345
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant chemotherapy until clinically indicated
Trial: 10374092
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue treatment (3 cycles prior to surgery)
Trial: 1423177
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg orally daily for 2 years
Trial: 1423177
Drug: PSK 3
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PSK 3 g orally daily for 2 years
Trial: 1423177
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with mitomycin C (MMC) and ftorafur (FT)
Trial: 6431470
Drug: Naloxone (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.7 to 1.0 micrograms/kg/min, total dose 8.8‐13.2 mg)
Trial: 6431470
Drug: Haloperidol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2 mg intramuscularly before sleep onset)
Trial: 15152279
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard medical treatment)
Trial: 25052698
Drug: Idarubicin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin at a maximum-tolerated dose (MTD) of 16 mg/m² IV on day 1, combined with high-dose methotrexate (3 g/m² IV), vindesine (3 mg/m² IV), and prednisolone (60 mg/m² IV/orally) on days 1-5.
Trial: 15627809
Drug: Slow-release caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release caffeine (SRC) 300 mg twice a day
Trial: 12435461
Drug: Systemic lidocaine
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic lidocaine (2mg/kg bolus for 5 min followed by 2mg/kg/h infusion for 40 min)
Trial: 12435461
Drug: Cumulative doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative doses of systemic lidocaine (0.5-2mg/kg) injected 30 min after incision
Trial: 25043647
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (a nitric oxide donor) given for seven days
Trial: 25043647
Drug: Continuing pre-stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing pre-stroke antihypertensive therapy
Trial: 25043647
Drug: Stopping (temporarily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping (temporarily for seven days) pre-stroke antihypertensive drugs
Trial: 16401155
Drug: High-dose divalproex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose divalproex
Trial: 16401155
Drug: Low-dose divalproex
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose divalproex
Trial: 12771535
Drug: High-flux dialyzers
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flux dialyzers (e.g. cellulose triacetate, polymethylmethacrylate) or hemodiafiltration
Trial: 8610383
Drug: Pentoxifylline (PTF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTF) 800 mg q 8 hr for at least 24 h
Trial: 1467165
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion (CIV) of morphine
Trial: 1467165
Drug: Intermittent parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent parenteral opioids (IPO)
Trial: 1467165
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation (50% O2)
Trial: 6369238
Drug: Phenobarbital treatment
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital treatment (two loading doses of 10 mg/kg 12 hours apart, followed by a maintenance dose of 2.5 mg/kg every 12 hours for 6 days)
Trial: 29765213
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 μg once-daily add-on therapy
Trial: 20228999
Drug: Propofol continuous
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol continuous infusion (0.8 mg/kg induction dose and 3 mg/kg/h maintenance dose)
Trial: 20228999
Drug: Intermittent midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermittent midazolam injection (mean total dose 10.3 +/- 4.5 mg)
Trial: 15602505
Drug: Low-dose liquid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose liquid fluoxetine (mean final dose: 9.9±4.35 mg/day)
Trial: 15602505
Drug: Liquid fluoxetine
RxNorm normalized name: fluoxetine Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid fluoxetine
Trial: 27502323
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (ACT) guided by the 15-gene expression signature
Trial: 27502323
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (ACT) guided by clinical stage
Trial: 17953678
Drug: Neutral pH
RxNorm normalized name: Gelato Neutral pH 2 % Oral Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral pH superoxidised aqueous solution (NpHSS)
Trial: 12429535
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) treatment starting at 7.5 mg/week, increased to a maximum of 25 mg/week if necessary
Trial: 402671
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (imipramine and amitriptyline)
Trial: 23889217
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (3 tablets daily of 25 mg micronized DHEA for at least 12 weeks) in young women under 40 years
Trial: 23889217
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (3 tablets daily of 25 mg micronized DHEA for at least 12 weeks) in women over 40 years
Trial: 23080088
Drug: Drug Eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Eluting Stent (DES) - Paclitaxel eluting stent (Chopin Luc(TM), Balton, Poland)
Trial: 19032573
Drug: Nicotine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.5 mg/kg s.c.) administered via 10 injections every second day starting from postnatal day 27 for adolescents and day 75 for adults.
Trial: 19032573
Drug: Nicotine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.5 mg/kg) administered to challenge animals after initial treatment.
Trial: 15009842
Drug: Azithromycin (5-days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (5-days treatment)
Trial: 15009842
Drug: Metronidazole (7-days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (7-days treatment)
Trial: 11152432
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of azithromycin (1.5 g)
Trial: 11152432
Drug: 3 day
RxNorm normalized name: Kathro 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 day regimen of azithromycin (500 mg/day)
Trial: 9471423
Drug: Octreotide 100
RxNorm normalized name: 1 ML octreotide 100 MCG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 100 micrograms subcutaneously, three times daily for two days
Trial: 7952561
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial prophylaxis (TAP) with tobramycin, colistin, and amphotericin B administered in oropharynx and stomach.
Trial: 7952561
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical antimicrobial prophylaxis (Control Group 2).
Trial: 7952561
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical antimicrobial prophylaxis (Control Group 3).
Trial: 7952561
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial prophylaxis (TAP) (Group 1).
Trial: 3608351
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg intravenous trazodone
Trial: 3608351
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral trazodone
Trial: 30425247
Drug: Low-gluten diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-gluten diet (2 g gluten per day)
Trial: 30425247
Drug: High-gluten diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-gluten diet (18 g gluten per day)
Trial: 27076370
Drug: Lidocaine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (intravenous bolus of 1.5 mg/kg at induction of anesthesia, followed by an infusion of 1.5 mg · kg · h until 30 minutes after PACU arrival)
Trial: 22251024
Drug: Other sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other sleep medications
Trial: 18399256
Drug: Oral immunonutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunonutrition (Impact Oral) for 7-10 days before surgery
Trial: 10066840
Drug: Nadroparin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (180 anti-factor Xa units/kg per 24 hours) for 3 weeks followed by oral anticoagulants for 3 months
Trial: 7030714
Drug: 5-nitrox (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-nitrox (200 to 250 mg, mean 3 mg/kg of body weight)
Trial: 7030714
Drug: 5-nok (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-nok (administered under the same conditions)
Trial: 17910331
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray, 1 spray per nostril twice daily
Trial: 15475903
Drug: Cyclo-oxygenase-2 (COX-2)
RxNorm normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclo-oxygenase-2 (COX-2) inhibitors
Trial: 15475903
Drug: Paracetamol 600/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 600/650 mg plus codeine 60 mg
Trial: 9760898
Drug: TiO‐blasted implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiO‐blasted implants
Trial: 9760898
Drug: Both types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both types of implants
Trial: 7802196
Drug: Plasma‐Lyte 148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma‐Lyte 148 (magnesium‐containing crystalloid solution)
Trial: 7802196
Drug: Compound sodium
RxNorm normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound sodium lactate solution (maintenance crystalloid)
Trial: 31218842
Drug: Neoadjuvant dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant dual anti-HER2 therapy and taxane
Trial: 22592572
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C daily